ARID1A
1 clinical trials · Condition
| Record | Firm | Date |
|---|---|---|
| PD-1 Combined With Dasatinib for as Third-line Treatment for ARID1A Mutation Advanced NSCLC (NCT04284202) | The Affiliated Hospital of Qingdao University | 2020-03-01 |
Track ARID1A automatically
Every clearance here is in the API, with alerts when new ones post.